Announcement on Subscription of Private Equity Shares
Securities code: 600201 Securities abbreviation: Biology Shares Announcement number: Lin 2026-032
Jinyu Biotechnology Co., Ltd.
Announcement on Subscribing Private Equity Fund Shares
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
Private equity fund manager: Chenxi (Shenzhen) Private Equity Investment Fund Management Co., Ltd.
Private equity fund custodian: Cathay Haitong Securities Co., Ltd.
Name of private equity fund: Chenxi Haoran Core No. 2 Private Equity Investment Fund
Investment amount: RMB 50 million
This transaction does not constitute a related transaction
This transaction does not constitute a major asset restructuring
Approval procedures completed: This investment is within the approval authority of the company's management and does not need to be submitted to the company's board of directors and shareholders' meeting for review and approval. The company's management is responsible for signing the investment fund contract and exercising relevant responsibilities and rights in accordance with the contract.
Risk warning
The private equity funds invested by the company this time have no capital guarantee or minimum return commitments. Private equity funds may have capital loss risks, fund operation risks, liquidity risks, policy risks, operational or technical risks, force majeure risks, etc. The company may face risks such as uncertainty of investment returns, risks of changes in fair value affecting the company's profits and losses, operational or technical risks, and other risks.
1. Basic information on subscribing for private equity fund shares
In order to improve the company's capital utilization efficiency and increase the company's income, without affecting normal production and operations and effectively controlling risks, Jinyu Baoling Biopharmaceuticals Co., Ltd. (hereinafter referred to as "Jinyu Baoling"), a wholly-owned subsidiary of Jinyu Biotechnology Co., Ltd. (hereinafter referred to as the "Company"), and Chenxi (Shenzhen) Private Equity Investment Fund Management Co., Ltd. (hereinafter referred to as "Chenxi Investment") and Cathay Haitong Securities Co., Ltd. (hereinafter referred to as "Cathay Haitong") recently jointly signed the "Chenxi Haoran Core No. 2 Private Securities Investment Fund Private Equity Fund Contract". The company plans to use its own funds of 50 million yuan to subscribe for the Chenxi Haoran Core No. 2 Private Securities Investment Fund.
According to the relevant provisions of the "Shanghai Stock Exchange Stock Listing Rules" and the "Articles of Association", this investment is within the approval authority of the company's management and does not need to be submitted to the company's board of directors and shareholders' meeting for review and approval. The company's management is responsible for signing the investment fund contract and exercising relevant responsibilities and rights in accordance with the contract.
This external investment does not constitute a related transaction, nor does it constitute a major asset reorganization as stipulated in the "Administrative Measures for Major Asset Reorganization of Listed Companies".
2. Specific information on subscription of private equity fund shares
- Basic information of the fund
Fund name Chenxi Haoran Core No. 2 Private Securities Investment Fund
Fund number SBND55
Name of fund manager Chenxi (Shenzhen) Private Securities Investment Fund Management Co., Ltd.
The total amount raised by this fund during the fundraising period shall not be less than RMB 1,000 Fund size (10,000 yuan)
Ten thousand yuan.
Organizational form Equity private securities investment fund
Date of establishment February 3, 2026
Duration 20 years
Filing time March 10, 2026
- Basic information of the fund manager
Legal person Chenxi (Shenzhen) Private Securities Investment Fund Management Co., Ltd.
Enterprise type limited liability company (sole proprietorship by Hong Kong, Macao and Taiwan legal persons)
Unified social credit code 91440300MA5GXDJA9L
Registration code P1072868
Filing time December 14, 2021
Legal representative Xiang Yanxiang
Date of establishment August 4, 2021
Registered capital US$5 million
Private securities investment fund management. (You must complete registration with the Asset Management Association of China before you can engage in business activities) (You are not allowed to engage in business scope trust, financial asset management, securities asset management and other restricted projects; you are not allowed to raise funds in a public way to carry out investment activities; you are not allowed to engage in publicly raised fund management business) None
Registered address in front of No. 5033 Menghai Avenue, Nanshan Street, Qianhai Shenzhen-Hong Kong Cooperation Zone, Shenzhen City
L29-03, Building 3, Haiyue Financial Center
Is he a person subject to execution for breach of trust? No
The company and its subsidiaries have no relationship with Chenxi Investment. Morningside Investment does not hold shares in the company and does not plan to hold shares during the life of this product. Is there any related relationship?
Company shares. The company and its subsidiaries have no other interest relationships with Chenxi Investment.
- Basic information of the fund custodian
Legal person Cathay Haitong Securities Co., Ltd.
Enterprise type Other joint stock limited company (listed)
Unified social credit code 9131000063159284XQ
Legal representative Zhu Jian
Date of establishment: August 18, 1999
Registered capital 17,628,925,829 yuan
Licensed items: securities business; securities investment consulting; securities companies provide intermediary introduction services to futures companies. (Projects that require approval according to law can only carry out business activities after approval by relevant departments. The specific business scope of the business project
Subject to approval documents or licenses from relevant departments) General items: Securities financial advisory services. (Except for projects that require approval according to law, business activities can be carried out independently with a business license and in accordance with the law)
Registered address: Cathay Haitong Building, No. 768, Nanjing West Road, Jing'an District, Shanghai
Is he a person subject to execution for breach of trust? No
The company and its subsidiaries have no related relationship with Cathay Haitong, nor does it exist whether there is any related relationship.
Other interests.
3. Main contents of the fund contract
Private equity fund manager: Chenxi (Shenzhen) Private Equity Investment Fund Management Co., Ltd. Private equity fund custodian: Cathay Haitong Securities Co., Ltd.
Fund share holder: Jinyu Baoling Biopharmaceutical Co., Ltd.
(1) Fund name: Chenxi Haoran Core No. 2 Private Securities Investment Fund
(2) How the fund operates: open-ended
(3) Fund duration: 20 years
(4) The initial fundraising face value of the private equity fund shares: The initial fundraising face value of the fund shares is 1.00 yuan, and the subscription price is 1.00 yuan per share.
(5) Custody matters of private equity funds: The private equity fund custodian of this fund is Cathay Haitong Securities Co., Ltd. The private equity fund custodian has obtained the securities investment fund custody qualification approved by the China Securities Regulatory Commission.
(6) Subscription and redemption rates
Subscription rate: The subscription rate for this fund is 1%. The manager has the right to reduce or reduce the subscription fee.
Redemption rate: If the holding period of the Fund's shares is less than 180 days, the redemption rate is 1%, and if the holding period is 180 days or more, the redemption rate is 0%.
(7) Rights of fund unit holders
(1) Obtain fund property income;
(2) Obtain the remaining fund assets after liquidation;
(3) Subscription, redemption and transfer of fund shares in accordance with the provisions of the fund contract;
(4) In accordance with the provisions of the fund contract, participate in or apply to convene a general meeting of fund unit holders and exercise relevant powers;
(5) Supervise the performance of investment management by private equity fund managers and the performance of custody obligations by private equity fund custodians;
(6) Obtain fund information disclosure materials in accordance with the time and method stipulated in the fund contract; (7) If the private equity fund manager or private equity fund custodian violates laws and regulations or the provisions of the fund contract, resulting in damage to legitimate rights and interests, the right to receive compensation;
(8) Other rights stipulated in relevant national laws and regulations, regulatory agencies and this contract.
(8) Investment by private equity funds
Investment objectives: This fund constructs an investment portfolio based on in-depth research, and strives to create stable income and returns for investors while strictly controlling investment risks.
Investment scope:
(1) Equity: stocks traded on stock exchanges (including but not limited to new share subscriptions, preferred shares, non-public issuance of stocks by listed companies, etc.), depositary receipts traded on stock exchanges.
(2) Fixed income: bank demand deposits, cash, treasury bonds, central bank bills, policy financial bonds, local government bonds, asset-backed securities traded on stock exchanges or inter-bank markets, stock exchange pledged quotation repos, convertible bonds, and exchangeable bonds.
(3) Futures and derivatives: derivatives traded on stock exchanges and futures exchanges (including but not limited to futures, options, warrants, etc.), OTC derivatives (including but not limited to income swaps and OTC options).
(4) Others: Securities allowed for investment under the interconnection mechanism between domestic and overseas securities markets (including but not limited to stocks, depository receipts, funds, etc.), public funds, bond repurchases, securities company income certificates, refinancing securities lending transactions (that is, the Fund lends the securities it holds to securities finance companies as the subject securities of securities lending), and margin trading and securities lending transactions. If the assets listed in this article involve the aforementioned asset categories, they will be included in the calculation of the corresponding asset category.
(9) Risk and return characteristics of private equity funds
This fund belongs to the [R5] risk investment variety and is suitable for ordinary qualified investors and professional investors with risk identification, assessment and tolerance [C5].
(10) Fund fee accrual methods, accrual standards and payment methods
Fund management fee: The fund’s management fee is an annual fee of 1.5%.
Fund custody fee: The fund’s custody fee is an annual rate of 0.01%.
Fund operation service fee: The fund’s operation service fee is an annual rate of 0.01%.
Performance remuneration of the fund: the accrual ratio is 20%. The calculation of performance remuneration adopts the single high-water mark net value method of a single investor, that is, the cumulative net value of each fund share or redemption share of each type of fund share holder is greater than the last successful accrual base date (when accruing for the first time, it is the total net value of each fund share or redemption share on the participation day). When the accumulated net value of each category of fund shares is calculated separately for each share, the difference in the growth of the cumulative net value of each category of fund shares during the holding period from the last successful accrual base date to the current accrual base date will be calculated separately, and the portion of the accumulated net value of each category of fund shares that exceeds the last successful accrual base date will be accrued at an agreed ratio.
(11) Income distribution of private equity funds
Composition of fund profits: Fund profits refer to the balance of the fund’s interest income, investment income, changes in fair value and other income generated by fund operations after deducting management fees, custody fees, operating service fees and other expenses generated by fund operations.
Fund profit available for distribution: Fund profit available for distribution refers to the cumulative undistributed profit of the fund as of the income distribution base date, including realized gains and unrealized gains in undistributed profits.
After fund income distribution, the net value of fund shares shall not be lower than the face value, that is, the net value of fund shares on the base date of fund income distribution minus the income distribution amount per unit of fund share shall not be lower than the face value.
The fund’s income distribution method is cash or dividend reinvestment. This fund adopts the dividend reinvestment method by default, and the specific method of income distribution shall be subject to the income distribution plan issued by the manager. In particular, if the dividend reinvestment method is adopted, the lock-in period and redemption fee (if any) will be waived for the dividend reinvested shares.
Each fund share of the same type enjoys equal distribution rights.
The income distribution ratio, distribution frequency, distribution time and distribution amount during the duration of the fund shall be determined by the private equity fund manager.
(12) Liability for breach of contract
In the process of realizing their respective rights and performing their respective obligations, private fund managers, private fund custodians and fund investors shall bear corresponding responsibilities if they violate the provisions of laws, administrative regulations or the provisions of this contract; for direct losses caused to fund property or other parties to this contract, they shall bear liability for compensation for their respective actions in accordance with the law. If this contract can continue to be performed, it shall continue to be performed.
In the event of a breach of contract by one or more parties, this contract shall continue to be performed if it can continue to be performed on the premise of protecting the interests of fund shareholders to the greatest extent possible. The non-breaching party is obliged to take necessary measures in a timely manner within the scope of its duties to prevent the expansion of losses. If the failure to take appropriate measures results in further expansion of losses, compensation shall not be claimed for the expanded losses. The non-breaching party shall bear the reasonable expenses incurred by the non-breaching party to prevent the expansion of losses.
If a business error occurs that is not caused by the private equity fund manager or private equity custodian, although the private equity fund manager and private equity fund custodian have taken necessary, appropriate, and reasonable measures to conduct inspections, the error cannot be discovered or the error cannot be updated in a timely manner due to the aforementioned reasons, resulting in losses to fund property or fund investors, the private equity fund manager and private equity fund custodian are exempt from liability for compensation. However, private equity fund managers and private equity fund custodians should actively take necessary measures to eliminate or mitigate the resulting impact.
The losses that one party shall compensate the other party for under this contract shall be limited to direct losses.
4. Impact on listed companies
The purpose of this investment is to improve the efficiency of the company's own funds, make rational use of idle own funds, and increase investment returns. This investment is based on the premise of ensuring the company's daily operating capital needs. The source of funds is the company's own idle funds. It will not affect the normal development of the company's main business, nor will it have a significant impact on the company's operating performance.
5. Risk warning
The fund invested this time is a private equity investment fund. There is no capital guarantee or minimum return commitment for this investment. The expected risk level is R5. The fund's equity asset investment accounts for no less than 80%. There is no early warning line or stop loss line. During the establishment and operation of the fund, there are risks including but not limited to capital loss risks, fund operation risks, liquidity risks, risks involved in private equity fund outsourcing matters, fundraising failure risks and filing failure risks, fund industry association information backup system query risks, tax risks, market risks, investment management risks, credit risks, specific risks corresponding to specific investment objects, and specific design considerations of fund products. General risks such as risks of development; as well as risks involved in the entrusted raising of private equity funds, risks involved in the inconsistency between fund contracts and the China Asset Management Association's contract guidelines, related transaction risks, operation maintenance mechanisms and corresponding failure risks, corresponding risks in dispute resolution methods, risks in which the private equity fund custodian is restricted in the performance of its investment supervision duties, risks in which the private equity fund manager's own risk control measures fail, and other special risks.
The company has fully understood the risks associated with this investment, and will closely track fund operation management and investment operations, maintain regular communication with fund managers, regularly obtain fund operation reports and net value data, continue to pay attention to its asset allocation, operational performance and risk changes, strengthen post-investment risk management and control, and ensure the safety of the company's funds. Investors are kindly requested to invest with caution and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Jinyu Biotechnology Co., Ltd.
July 2, 2026